Optimizing Treatment Sequencing in Advanced Colorectal Cancer

Author(s):

Scott Soefje, PharmD, MBA, BCOP, FCCP, FHOPA ,Melody Chang, RPh, MBA, BCOP

Experts discuss additional factors considered when determining the most effective sequence of therapies for metastatic colorectal cancer, including fruquintinib, regorafenib, and trifluridine + tipiracil ± bevacizumab, and explore the further research needed to understand optimal sequencing of these treatments better.

EP: 1.Treatment Options in mCRC: A Clinical Overview

EP: 2.Comparing Safety Profiles: Making Informed Treatment Decisions in mCRC

EP: 3.Quality of Life and Patient Outcomes in mCRC Treatment

Now Viewing

EP: 4.Optimizing Treatment Sequencing in Advanced Colorectal Cancer

EP: 5.The Patient Journey: Mapping the Pharmacist’s Role in mCRC Management

EP: 6.Evolution of Oncology Pharmacy Practice in mCRC

EP: 7.Pharmacist-Led Strategies for Adverse Event Management in mCRC

EP: 8.Navigating Cost Considerations in Treatment Selection of mCRC Agents

EP: 9.Best Practices for Overcoming mCRC Prior Authorization Barriers

EP: 10.Building Better Collaboration: Reducing Care Delays in Managing mCRC

Video content above is prompted by the following:

What additional factors do you consider when determining the most effective sequence of these therapies (fruquintinib, regorafenib, trifluridine + tipiracil ± bevacizumab)?
What further research is needed to understand optimal sequencing of these therapies better?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!